BRIEF published on 10/30/2025 at 21:05, 5 months 9 days ago TME Pharma's Semi-Annual Report and Financial Restructuring Financial Results Biotechnology CEO Appointment Bond Issuance TME Pharma
PRESS RELEASE published on 10/30/2025 at 21:00, 5 months 9 days ago TME Pharma publishes its semi annual results and half-year report TME Pharma publishes semi annual results and half-year report showing cost reductions, new CEO, and fundraising activities. Focus on NOX-A12 and NOX-E36 assets Fundraising Cost Reductions TME Pharma NOX-A12 Semi Annual Results
PRESS RELEASE published on 09/01/2025 at 08:45, 7 months 8 days ago Inside Information: Other news releases TME Pharma completes August financing, with €500k cash received on August 28th, bringing cash position to €2.35M. Organization aims to attract financing for cancer and eye therapies Cash Position TME Pharma August Financing Cost-efficient Organization Novel Therapies
BRIEF published on 09/01/2025 at 08:45, 7 months 8 days ago TME Pharma successfully completes its August fundraising round Biotechnology Fundraising Treasury Cryptocurrencies Cancer
BRIEF published on 08/25/2025 at 08:05, 7 months 15 days ago TME Pharma Secures €500,000 through New Bond Issue Investment Strategy Cost Reduction Bond Issuance Financial Strategy Shareholder Commitments
PRESS RELEASE published on 08/25/2025 at 08:00, 7 months 15 days ago Inside Information / Other news releases TME Pharma to raise €500k through bond issue & receives new shareholding notice. CEO & Chairman also invest. Funds to boost financial position & support R&D projects & investment strategy Fundraising Shareholding CEO Bond Issue TME Pharma
BRIEF published on 07/08/2025 at 08:05, 9 months 1 day ago TME Pharma Terminates Liquidity Contract Amid Cost Optimization Liquidity Contract Biotechnology Refinancing Cost Optimization TME Pharma
PRESS RELEASE published on 07/08/2025 at 08:00, 9 months 1 day ago Inside Information / Other news releases TME Pharma terminates liquidity contract with Invest Securities to optimize costs. Improve trading volume of shares and healthy liquidity deemed contract unnecessary. Finds success in refinancing and reducing operational costs Liquidity Contract Cost Optimization Trading Volume Organizational Restructuring TME Pharma
BRIEF published on 05/21/2025 at 08:05, 10 months 19 days ago TME Pharma Enhances Financial Outlook with €1.7M Bond Commitments Strategic Partnerships Bond Issuance Clinical Programs Financial Visibility Cost Structure
PRESS RELEASE published on 05/21/2025 at 08:00, 10 months 19 days ago Inside Information / Other news releases TME Pharma extends financial visibility to May 2026 by securing €1.7M financing through regular bonds with attached warrants. CEO and board show strong commitment to company's success Clinical Programs TME Pharma Financial Visibility Regular Bonds Private Warrants
Published on 04/09/2026 at 16:00, 57 minutes ago Banff Half Marathon Completes 2025 Emissions Assessment, Supporting Climate Action with Karbon-X
Published on 04/09/2026 at 14:40, 2 hours 17 minutes ago Silver X Delivers Production Growth During the First Quarter of 2026
Published on 04/09/2026 at 14:00, 2 hours 57 minutes ago Orogen Royalties Announces Mineral Reserve and Resource Update on Producing Ermitaño Royalty
Published on 04/09/2026 at 13:30, 3 hours 27 minutes ago Datametrex Receives $6M Purchase Order for Data Centre from Fortune 500 Conglomerate
Published on 04/09/2026 at 13:30, 3 hours 27 minutes ago ESGold Advances Toward Production and Exploration Drilling as Mill Buildout Progresses in Parallel
Published on 04/09/2026 at 15:40, 1 hour 16 minutes ago Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
Published on 04/09/2026 at 15:39, 1 hour 17 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 04/09/2026 at 15:39, 1 hour 17 minutes ago Form 8.3 - The Vanguard Group, Inc.: British Land Company plc, The
Published on 04/09/2026 at 15:57, 59 minutes ago Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 9 hours 57 minutes ago bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Published on 04/08/2026 at 18:02, 22 hours 55 minutes ago Publication of the 2025 Universal Registration Document
Published on 04/08/2026 at 17:45, 23 hours 12 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 04/08/2026 at 12:58, 1 day 3 hours ago EURAZEO IS ASSIGNED A BBB CREDIT RATING (STABLE OUTLOOK) BY S&P AND A BBB CREDIT RATING (STABLE OUTLOOK) BY FITCH
